Cypherpunk Technologies Inc (CYPH)
NASDAQFinancialsAsset ManagementSnapshot 2026-09-04
$2.42+6.61%
Close 2026-09-04 · 1-day change
NASDAQFinancialsAsset ManagementSnapshot 2026-09-04
Broken: Primary pillar broken — Reduce negative cash flow from operations to at least -$3.4M by 2026-Q1: OCF -$35.2M vs -$3.4M.
Operating losses improved from -$16.1M in 2024-Q4 to -$4.8M in 2026-Q1. Cash from operations improved from -$15.5M to -$3.4M in the same period. The company is reducing losses and cash burn. Board transitions are managed to stabilize governance.
Net income remains volatile, swinging from -$77.2M to $40.4M but not consistently profitable. The company faces Nasdaq delisting risk due to low stock price. Cash flow is still negative and losses persist.
The market prices in a high risk with implied negative growth over 3-5 years and a fair value near $2.32. Our view aligns with the weak outlook and ongoing losses, reflecting the company's troubled financial state.
Breaks if: cash flow from operations remains below -$3.4M beyond 2026-Q1
Breaks if: stock price remains below $1.00 for 30 consecutive business days
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CYPH represents a speculative growth investment with a focus on advancing privacy technology and digital asset strategies. The current thesis state is cautious due to weak recent financial performance and high risk.
The market appears to price in a low level of fragility, suggesting that current valuations are relatively cheap compared to peers. However, expectations are tempered by the company's loss-making status and recent erratic earnings.
Management is making progress in reducing operating losses and advancing key projects, though recent financial performance remains weak. The near-term risk of missing earnings is notable, as the company has struggled with consistency in recent quarters.
The long-term thesis hinges on the performance of sector bellwethers like BLK, BX, and KKR, as well as the Federal Reserve's interest rate decisions. Positive developments in CYPH's cancer treatment and digital asset strategies could also influence outcomes.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Respond to Nasdaq notifications regarding minimum bid price and maintain listing compliance.
Stated as a priority in 2 of last 2 quarters. The Company received Nasdaq deficiency notices in 2026-Q1 and 2026-Q2 for closing bid price below $1.00. No financial improvement data is provided, so the trajectory is ongoing regulatory compliance focus with limited disclosed progress.
“Received Nasdaq notification letter for closing bid price below $1.00 for 30 consecutive business days.”
“Received Nasdaq Closing Bid Price Deficiency Letter notifying non-compliance with minimum bid price rule.”
Breaks if: operating income remains below -$4.8M beyond 2026-Q1
Over the next 1 to 3 years, CYPH's potential for recovery depends on external sector dynamics and internal execution on strategic priorities. Not investment advice.